Who is the manufacturer of Roflumilast-DALIRESP?

Roflumilast Tablets (Roflumilast)-DALIRESP is manufactured by AstraZeneca, a world-renowned pharmaceutical company. AstraZeneca is committed to researching, developing and manufacturing innovative medicines, mainly in the fields of respiratory system, oncology, cardiovascular disease, diabetes and so on.

In the field of respiratory system, AstraZeneca has been focusing on the development of treatments for chronic obstructive pulmonary disease (COPD) and asthma. Roflumilast, as one of its important products, reflects the company's profound professional knowledge and technological accumulation in the field of respiratory diseases. The medicine is designed to help improve quality of life and reduce exacerbations in COPD patients, reflecting AstraZeneca's focus and commitment to patient needs.

The approval and launch of roflumilast tablets is an important milestone for AstraZeneca in the field of chronic lung diseases. This drug effectively reduces the inflammatory response in COPD patients by selectively inhibiting phosphodiesterase 4 (PDE4), thereby improving their lung function and overall health. AstraZeneca has invested a lot of resources in promoting the clinical development of roflumilast and has verified its efficacy and safety through multiple randomized controlled trials, making it an important choice in the treatment of COPD.

In addition to developing new drugs, AstraZeneca is also committed to the production and distribution of drugs, ensuring that its products can be supplied timely and safely around the world. The company has production bases in many countries and regions and strictly follows international pharmaceutical production standards to ensure high standards of drug quality. At the same time, AstraZeneca is constantly seeking cooperation with other scientific research institutions and companies to promote innovation and development, hoping to provide effective treatment options for more patients.

Reference materials:https://www.daliresp.com/